The e antigen (HBeAg), recently discovered by Magnius and Espmark (6) , has attracted considerable interest because of its possible use as an indicator of viral infectivity as well as for its ability to predict the clinical outcome in patients infected with hepatitis B virus (HBV; 7, 10) . HBeAg is found only in type B hepatitis infections and is distinct from both the hepatitis B surface antigen (HBsAg) and the hepatitis core antigen (6, 12) . The fact that it is most commonly detected in the presence of circulating Dane particles and HBV-specific deoxyribonucleic acid (DNA) polymerase activity (9) has led to the suggestion that HBeAg and DNA polymerase activity may be identical (4 
